Regulation of Lupus Nephritis by Stat3

Wen-Hai Shao
Division of Rheumatology, Department of Medicine, Temple University, Philadelphia, USA

Corresponding author: Wen-Hai Shao, Division of Rheumatology, Department of Medicine, Temple University, Philadelphia, USA, Tel: +1-215-707-8751; E-mail: wshao@temple.edu

Received date: Nov 20, 2015; Accepted date: Dec 10, 2015; Published date: Dec 12, 2015

Lupus nephritis is often treated with immunosuppression, which can cause deleterious side effects, including increased risk of severe infections and malignancy. There remains a major void in the successful management of lupus nephritis. Presently, various inhibitory strategies to block Stat signalling and function are being pursued. For example, MRL/lpr mice treated with the selective Jak2 inhibitor (AG490, which inhibits both Stat1 and Stat3) had significantly reduced proteinuria and improved renal function [7]. In this regard, inhibition of both Stat1 and Stat3 signalling may hold therapeutic potential for LN. Our studies emphasize that there are complex interactions between different Stats that need to be considered as Jak-directed therapy becomes broadly accepted, because of the wide variety of cells that express Stats and the interest in exploiting them becomes more and more tantalizing.

References